A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
In the catabolism of uracil, the enzyme converts uracil to dihydrouracil using nicotinamide adenine dinucleotide phosphate (NADPH) as its cofactor. It can also act on thymine to give dihydrothymine. In humans the enzyme is encoded by the DPYD gene. It is the initial and rate-limiting step in pyrimidine catabolism. It is also involved in the degradation of the chemotherapeutic drugs 5-fluorouracil and tegafur. It participates in beta-alanine metabolism and pantothenate and coa biosynthesis.
Many of the opposition groups subsequently began competing for influence in the power vacuum that followed the ouster of Barre's regime. In the south, armed factions led by USC commanders General Mohamed Farah Aidid and Ali Mahdi Mohamed, in particular, clashed as each sought to exert authority over the capital. In 1991, a multi-phased international conference on Somalia was held in neighbouring Djibouti. Owing to the legitimacy bestowed on Muhammad by the Djibouti conference, he was subsequently recognised by the international community as the new President of Somalia. He was not able to exert his authority beyond parts of the capital. Power was instead vied with other faction leaders in the southern half of Somalia and with autonomous sub-national entities in the north. The Djibouti conference was followed by two abortive agreements for national reconciliation and disarmament, which were signed by 15 political stakeholders: an agreement to hold an Informal Preparatory Meeting on National Reconciliation, and the 1993 Addis Ababa Agreement made at the Conference on National Reconciliation. In 1998, the state of Puntland was established under the leadership of Abdullahi Yusuf, head of the Somali Salvation Democratic Front. In the early 1990s, due to the protracted lack of a permanent central authority, Somalia began to be characterised as a "failed state". Following the collapse of the Somali Democratic Republic in early 1991, a new phenomenon emerged – the establishment of Sharia courts to impose law and order on the volatile neighborhoods of Mogadishu.
Since fast food was unknown in the United States at the time of White Castle's founding, there was no infrastructure to support the business, as is common with today's fast-food restaurants. The company established centralized bakeries, meat supply plants, and warehouses to supply itself. It was said that the only things that they did not do themselves were raise the cows and grow their own wheat. Ingram developed a device to produce previously unheard of paper hats (for employees to wear as part of the uniform). In 1932, Ingram set up a subsidiary, Paperlynen, to produce these hats and other paper products used in his restaurants as well as for many other purposes. At the time, White Castle's distribution stretched from Wichita to New York. Ingram decided the central office should be in the center of the distribution area, and in 1936, relocated the central office to Columbus, Ohio. That same year, Ingram decided to close all of the restaurants in the two smallest-profit markets, Wichita and Omaha. In 1955, Paperlynen produced over 42 million paper hats worldwide with more than 25,000 different inscriptions.
==== Australia ==== 2C-B is controlled in Australia and on the list of substances subject to import and export controls (Appendix B). It was placed on Schedule One of the Drugs Misuse and Trafficking Act when it first came to notice in 1994, when in a showcase legal battle chemist R. Simpson was charged with manufacturing the substance in Sydney. Alexander Shulgin came to Australia to testify on behalf of the defense, to no avail. 2C-B is not specifically listed in the Australia Poisons Standard (October 2015), however similar drugs such as 2C-T-2 and 2C-I are making 2C-B fall under the Australian analogue act.
Sources: en.wikipedia.org
=== Angiogenesis === The formation of new blood vessels is essential for tumor survival and expansion. Intracrines like VEGF and angiogenin regulate angiogenesis within tumor cells and surrounding endothelial cells. Inhibiting intracrine trafficking of angiogenin to the nucleus has been shown to blunt cancer cell proliferation, making this an emerging therapeutic target.
Bully: Ryan Height: 6' (note: see weight below) Weight: 200 lbs. (height and weight not officially given. listed height and weight are claimed by brother in his video, but are likely estimations.) Fighter: Tony 'The Gun' Bonello Height: 6'2" Weight: 200 lbs. Victim(s): Alan (bully's older brother). Another victim named Nick appeared in a testimonial in Alan's video, but doesn't actually take part in the episode. Money earned by Bully: $2,000 Money earned by victim(s): $8,000 Original airing: Sunday, 22 March 2009
=== Etymology and terminology === The origin of the term dry needling is attributed to Janet G. Travell. In her 1983 book, Myofascial Pain and Dysfunction: Trigger Point Manual, Travell uses the term dry needling to differentiate between two hypodermic needle techniques when performing trigger point therapy. However, Travell did not elaborate on the details of the dry needling techniques: the injection of a local anesthetic and the mechanical use of a hypodermic needle without injecting a solution. The current techniques were based on traditional and Western medical acupuncture.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.